Needham analyst Gil Blum reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Buy and maintains $6 price target.
- Company Dashboard
- Filings
-
Article
Needham Reiterates Buy on Mereo BioPharma Group, Maintains $6 Price Target
Company Profile